The pipeline is bursting and many are more effective (longer lasting\better form factor). I think I count 18 from the main chart in this research paper...
>A new era for obesity treatment has commenced where pharmacotherapy with combinations of entero-pancreatic hormones approach the WL efficacy of bariatric surgery. Tirzepatide is the first dual agonist which has been approved for chronic weight management, but numerous other dual and/or triple agonists (cagrisema, retatrutide, mazdutide and survodutide) are also in phase 3 trials as potential treatments for obesity and its metabolic complications. Moreover, oral GLP-1 RA are also under development and will provide an alternative option.
>The plethora of efficacious obesity pharmacotherapies with different mechanisms of action will allow tailored treatment plans based on individual’s preference, comorbidities and treatment response. A percentage of people will not be able to tolerate the new pharmacotherapies or achieve the individualised goals and others may not have long-term access to these treatments. Combining different treatment modalities (including lifestyle interventions, pharmacotherapies and bariatric surgery) may support people to achieve individualised long-term goals, maximise health benefits and improve quality of life.
Speculation, but below is a search hit about companies with public GLP1 programs in the works. These would be companies hoping to make an improved drug (oral or better weight loss/tolerability properties). I am sure there are others with less visibility. Generics development is probably more stealthy. I think technically you are not allowed to use/test a competitor compound, but I am sure everyone does it.
Just speculation or got a link?